



## Association of *MTHFR*, *BMP4*, *TGFA* and *IRF6* Polymorphisms with Non-Syndromic Cleft lip and Palate in North Indian Patients

Kapil Kumar Avasthi<sup>1</sup>, Amit Agarwal<sup>2</sup>, and Sarita Agarwal<sup>1\*</sup>

1. Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow 226014, India

2. Department of Burn and Plastic Surgery, Vivekananda Polyclinic and Institute of Medical Sciences (VPIMS), Lucknow 226007, India

### Abstract

**Background:** Non-Syndromic Cleft Lip and Palate (NSCL/P) is a multifactorial birth defect. The world-wide prevalence of NSCL/P is 1 in 1000 live births; it differs with race, ethnicity and gender. The aim of the present study was to find out the status of candidate gene polymorphisms in NSCL/P cases and its association in phenotype of the patients.

**Methods:** We have screened five polymorphisms in four candidate genes *MTHFR* (rs1801133, rs1801131), *BMP4* (rs17563), *TGFA* (rs1146297) and *IRF6* (rs2235371) by restriction fragment length polymorphism and results were validated by Sanger sequencing. Our dataset consists of 200 NSCL/P cases and 200 healthy controls from the Indian population. Statistical data analysis was performed by SPSS software.

**Results:** *MTHFR* (rs1801133), *BMP4* (rs17563) and *TGFA* (rs1146297) gene polymorphisms showed significant association with NSCL/P and act as a risk factor in the Indian population ( $p < 0.05$ ). However, *MTHFR* (rs1801131), and *IRF6* (rs2235371) gene polymorphisms did not show significant association with NSCL/P in the Indian population.

**Conclusion:** The result of the study suggests an association between *MTHFR* (rs1801133), *BMP4* (rs17563) and *TGFA* (rs1146297) polymorphisms with NSCL/P in Indian population.

*Avicenna J Med Biotech* 2022; 14(2): 175-180

**Keywords:** BMP4, Indian population, IRF6, MTHFR, NSCL/P, TGFA

### Introduction

Non-Syndromic Cleft Lip and Palate (NSCL/P) is the world's second most prevalent congenital birth defect, with incidence of 1 in 700 live births and varies by ethnicity or geographical region. Balaji *et al*, reported a prevalence of NSCL/P 1.3 in 1000 live births in India<sup>1</sup>. Since patients of NSCL/P suffer with problems of feeding, speech difficulties, malnutrition, hearing injuries, infections and mental disorders from birth to adulthood, they need multidisciplinary care like surgical or dental treatment, speech therapy and psychosocial interventions throughout life<sup>2</sup>. A sequence of closely orchestrated events are needed during development of lip and palate formation, including cell proliferation, growth, differentiation and apoptosis. The disruptions in any of these events affects unacceptable facial structure morphology resulting in manifestation of disease<sup>3,4</sup>. Thus it is considered as a complicated

hereditary disorder but polygenic in nature. Shi *et al*, reported involvement of environmental risk factors like tobacco, smoke and alcohol intake during early pregnancy<sup>5</sup>.

Epidemiological surveys and animal model studies have also shown that antiepileptic medications or hormonal treatment, are the risk factor for NSCL/P<sup>6</sup>. In past linkage analysis, association studies, direct sequencing, and more recently genome-wide association studies have been done in relation to NSCL/P and found suitable for genetic predisposition studies<sup>2</sup>. Approximately 20 gene loci are identified in NSCL/P etiology, among those genes; we have selected five polymorphisms from four genes for present study, which are *MTHFR* (rs1801135, rs1801131), *BMP4* (rs17563), *TGFA* (rs1146297) and *IRF6* (rs2235371).

Methylenetetrahydrofolate reductase (MTHFR) is

one of the most important enzymes which plays a crucial role in the folate metabolism regulation. The gene coding for MTHFR is on the long arm of chromosome 1 (1p36.3), which contains 11 exons<sup>7</sup>. MTHFR (C677T and A1298C) has two common single nucleotide polymorphisms responsible for a moderately variable enzymatic action. MTHFR gene polymorphism studies have been reported from several regions suggesting a strong association with NSCL/P. Bone Morphogenetic Proteins (BMPs) plays an important role in the fusion of the upper lip, main palate, and craniofacial growth, primarily expressed in palatal shelf epithelial and mesenchymal cells<sup>8-10</sup>. Saket *et al*, have suggested that the polymorphism of BMP4 (rs17563) variant plays a significant role in the frequency of CL/P in the Iranian population<sup>11</sup>. The importance of BMP4 (rs17563) variations in the development of CL/P was addressed in previous investigations<sup>9,10</sup>. Throughout craniofacial growth, TGF $\alpha$  is expressed in the inner epithelium boundary of fusing palatal shelves and activates the extracellular matrix synthesis<sup>12,13</sup>. Ardinger *et al*, and Ebadifar *et al*, assessed the role of TGFA gene polymorphism in the event of CL/P and results show a strong association<sup>14,15</sup>. Interferon Regulatory Factor 6 (IRF6) is a transcription factor and is located on chromosome 1q32.3-q41<sup>16</sup>. IRF6 gene assembly consists of a highly conserved helix-turn-helix DNA-binding domain and a less conserved protein binding domain. The IRF6 gene is the gene between the candidates involved in both syndromic and non-syndromic form CL/P, with variations in this gene associated with van der Woude syndrome<sup>17</sup>. The IRF6 gene polymorphism rs2235371 is well established in many studies of NSCL/P<sup>18</sup>.

As the genetic diversity of NSCL/P is present in different ethnic groups, the role of these gene remains speculative in Indian populations; therefore, in this study, we have aim to investigate the association of genetic polymorphism of MTHFR, BMP4, TGFA, and IRF6 in NSCL/P in Indian population.

## Materials and Methods

### Study design and ethical approval

This study was carried out from September 2017 to December 2020 in the Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow. The research was carried out according to the World Medical Association (Declaration of Helsinki) for Experiments in humans. The study was approved by the Institutional Ethical Committee (IEC No: 2018-107-EMP-EXP) and informed consent was obtained from cases and controls.

### Sample collection

NSCL/P patient's sample (n=200, age=7 $\pm$ 5 years) and age and sex matched healthy controls (n=200, age=7 $\pm$ 5 years) were recruited for the study, after signed informed consent was obtained from patients and parents. The exclusion criteria for NSCL/P cases

were patients with any other history of developmental disorder, Syndromic form of CL/P (*e.g.*, eye, brain, limb anomalies and cardiac defects). The healthy controls were Indian healthy children without cleft lip and palate and other known genetic diseases.

### Genotyping analysis

**DNA isolation:** Genomic DNA was extracted from 3 ml peripheral venous blood samples of patients and controls. DNA was extracted by using standard Phenol-chloroform method, quantification of the DNA was measured by spectrophotometer at wavelength of 260 nm and the quality was checked on 0.8% agarose gel.

### Restriction fragment length polymorphism (RFLP)

Primers were designed to amplify candidate gene variants MTHFR (C677T, A1298C), BMP4 (T<C), and TGFA (A<C). Polymerase Chain Reaction (PCR) performed details of primers, annealing temperature and restriction sites are mentioned in table 1. The PCR amplified products were digested using restrictions enzymes (HinfI for C677T, MboII for A1298C, HphI for T<C and BamHI for A<C) and were kept at 37°C overnight; products were visualized by standard Ethidium Bromide-Agarose Gel Electrophoresis method (Figures 1-4).

### Sanger sequencing

Sanger sequencing was done for the IRF6 (G<A) gene polymorphism followed by amplification and PCR product purification. Sequencing of PCR products were performed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, California, United States), and products were resolved on the ABI 3130XL Genetic Analyser (Applied Biosystems). Sequence electro-pherograms were analysed using Finch TV (Figure 1-5).

### Statistical analysis

Genotype and allele frequency distributions of MTHFR BMP4, TGFA and IRF6 polymorphisms were calculated by counting the genotypes and compared with the predicted values using the chi-square test, based on the assumption of Hardy-Weinberg equilibrium. The Odds Ratios (OR) were calculated with the 95% confidence intervals (95% CI) and p-values <0.05 were considered to be significant. All analyses were performed using SPSS for Windows, version 18.0 (SPSS Inc., Chicago, USA).

## Results

This study consisted of 200 NSCL/P patients (102 males, 98 females) and 200 healthy individuals (105 males, 95 females). The observed genotype frequencies of cases and controls in all polymorphic sites were in Hardy-Weinberg equilibrium. The genotyping results, OR (95% CI) and p-value calculations for five Single Nucleotide Polymorphisms (SNPs) of the MTHFR (rs1801133, rs1801131), TGFA (rs1146297), BMP4 (rs17563) and IRF6 (rs2235371) are reported in table 2 (Figures 1-5).

Table 1. Candidate gene Variants Details.

Genes	Variant/ Alleles	Ch. Loc	Role	Primers for PCR amplification (5'-3')	Annealing Temp (°C)	PCR product length (bp)	Restriction enzymes	Genotypes
<b>MTHFR</b>								
	rs1801133	1p36.3	Nutritional	F 5'-TGAAGGAGAAGGTGTCTGCCGGA-3' R 5'-AGGACGGTCCGGTGAGAGTG-3'	62	198	Hinfl	CC-198 CT-198, 175 TT-175
	rs1801131		metabolism	F 5'-CTTTGGGGAGCTGAAGGACTACTAC-3' R 5'-CACTTTGTGACCATTCCGGTTTG-3'	62	163	MboII	AA-163 AC-84, 51, 28 CC-51, 28
<b>BMP4</b>	rs17563	14q22-q2	Transcription factors	F 5'-CCTAACTGTGCCTAG-3' R 5'-CATAACCTCATAAATGTTTATACGG-3'	56	197	HphI	TT-197 TC-197,110,87 CC-110,87 AA-174
<b>TGFA</b>	rs11466297	2p13.3	Growth factors	F 5'-GCCTGGCTTATTGGGGATT-3' R 5'-AAGGGCAAGGAAACACAGG-3'	58	174	BamHI	AC-174,120,54 CC-120,54
<b>IRF6</b>	rs2235371	1q32.2	Immune system	F 5'-GAGTCACAGGGATGAACAGG-3' R 5'-GCTTCTGCTTCTCATTGGTA-3'	55	263	Sanger Sequencing	GG GA AA




Figure 1. Restriction fragment length polymorphism result of MTHFR rs1801133 (C>T).




Figure 3. Restriction fragment length polymorphism result of BMP4 rs17563 (T>C).




Figure 2. Restriction fragment length polymorphism result of MTHFR rs1801131 (A>C).




Figure 4. Restriction fragment length polymorphism result of TGFA rs11466297 (A>C).

Findings revealed that *MTHFR* rs1801133 (OR=1.56, 95% CI: 1.02-2.39, p=0.041), *BMP4* rs17563 (OR=1.85, 95% CI: 1.19-2.89, p=0.005) and *TGFA* rs1146297 (OR=1.69, 95% CI: 1.01-2.82, p=0.045) polymorphisms are significantly associated with NSC-

L/P. Our findings did not support an association between *MTHFR* rs7224837 and *IRF6* rs861019 polymorphisms and risk/protection of NSCL/P (Table 2).

### Discussion

The aetiology of orofacial clefts remains largely unknown, although genetic factors are thought to play the most important roles. There is compelling evidence

Candidate Gene Polymorphism Association with NSCL/P




Figure 5. Sanger Sequencing result of IRF6 rs2235371 (G>A).

Table 2. The genotype and allele frequency of the MTHFR, BMP4, TGFA and IRF6 polymorphisms in the case and control groups

Gene/SNPs	Genotype/Allele	Controls n=200 (%)	Cases n=200 (%)	OR (95% CI)	p-value
<b>MTHFR (rs1801133)</b>					
	CC	135 (67.5)	109 (54.5)	Referent Genotype	
	CT	58 (29)	73 (36.5)	1.56 (1.02-2.39)	0.041*
	TT	7 (3.5)	18 (9)	3.18 (1.28-7.90)	0.012
	C	328	291	Reference Allele	
	T	72	109	1.70 (1.21-2.39)	0.001
<b>MTHFR (rs1801131)</b>					
	AA	159 (79.5)	150 (75)	Referent Genotype	
	AC	38 (19)	46 (23)	1.28 (0.79-2.08)	0.312
	CC	3 (1.5)	4 (2)	1.41 (0.31-6.42)	0.654
	A	356	346	Reference Allele	
	C	44	54	1.26(0.82-1.93)	0.281
<b>BMP4 (rs17563)</b>					
	TT	139 (69.5)	110 (55)	Referent Genotype	
	TC	49 (24.5)	72 (36)	1.85 (1.19-2.89)	0.005*
	CC	12 (6)	18 (9)	1.90 (0.88-4.10)	0.104
	T	327	292	Reference Allele	
	C	73	108	1.66 (1.18-2.31)	0.003
<b>TGFA (rs11466297)</b>					
	AA	161 (80.5)	143 (71.5)	Referent Genotype	
	AC	30 (15)	45 (22.5)	1.69 (1.01-2.82)	0.045*
	CC	9 (4.5)	12 (6)	1.50 (0.61-3.67)	0.372
	A	352	331	Reference Allele	
	C	48	69	1.53 (1.02-2.28)	0.036
<b>IRF6 (rs2235371)</b>					
	GG	167 (83.5)	152 (76)	Referent Genotype	
	GA	28 (14)	40 (20)	1.59 (0.93-2.69)	0.087
	AA	5 (2.5)	8 (4)	1.77 (0.57-5.55)	0.321
	G	364	344	Reference Allele	
	A	36	56	1.64 (1.05-2.56)	0.027

suggesting that common genetic variations contribute to NSCL/P susceptibility<sup>2</sup>. In this study, we systematically evaluated the associations between a comprehensive panel of five polymorphisms of the four genes *MTHFR*, *BMP4*, *TGFA* and *IRF6* involved in NSCL/P. *MTHFR* C677T allele will increase the incidence of NSCL/P in Asian and Chinese populations<sup>19,20</sup>. Furthermore, *MTHFR* 677TT homozygotes are associated with NSCL/P and 677CT heterozygotes is the minor risk factor. However, a study from southern Han Chinese population reported involvement of *MTHFR* 677CT in cleft lip only<sup>21</sup>. Studies from southern and northern part of India also reported association between *MTHFR* C677T and NSCL/P<sup>22,23</sup>. Studies reported from China and Thailand showed no association between *MTHFR* C1298A allele risk factor for NSCL/P, which supports our results<sup>24-27</sup>. Also *MTHFR* A1298C poses no risk of any combination with NSCL/P in the eastern Uttar Pradesh<sup>23</sup>.

Several studies reported earlier have shown that *BMP4* may be involved in CL/P formation. Hu, *et al* found in meta-analysis, depending on the ethnicity range, the *BMP* rs17563 variant plays a different role in NSCL/P. This variant significantly increased the risk of NSCL/P in the Chinese population, while the Brazilian population showed a protective effect<sup>28,29</sup>. By contrast, Chen *et al*, reported that this variant was not associated with NSCL/P in the Asian population<sup>30</sup>.

First report in NSCL/P with *TGFA* gene polymorphisms was reported by Ardinger *et al*, and shows significant association with *TGFA* rs11466297<sup>14</sup>. Several studies have been published on *TGFA*. Studies of British, Japanese and French populations indicate involvement of the *TGFA* rs11466297 polymorphism in the occurrence of NSCL/P (31-33). Lidra *et al*, from Philippines published a contradictory study; it may be due to genetic differences in different populations<sup>34</sup>. Past research findings are contradictory and may be due to variations in sample size, demographic history and environmental conditions. Ebadifar *et al*, found that there is a link between BamHI variant polymorphism and prevalence of CL/P in the Iranian community, so that the incidence of AC genotype and C allele in the patient sample was substantially higher<sup>15</sup>.

Zucchero *et al* investigated 36 SNPs in *IRF6* gene in 10 populations including Asian, European and American; among these *IRF6* gene polymorphism rs2235371 was reported as a risk factor for NSCL/P in Filipinos of Asia<sup>16</sup>. Association studies between *IRF6* gene rs2235371 polymorphism and NSCL/P are well documented in Norway and western Chinese population<sup>35,36</sup>. Rahimnov *et al*, reported a lack of involvement of polymorphism rs2235371 and NSCL/P in the Brazilian population<sup>18</sup>. A study in south Indian population indicated *IRF6* (rs2235375) gene polymorphism is significantly associated with increased risk of NSCL/P<sup>37</sup>. Study from eastern part of Uttar Pradesh reported minor risk of *IRF6* 820GG with NSCL/P<sup>23</sup>.

## Conclusion

The present study assessed the interaction effects of *MTHFR* (rs1801133, rs1801131), *BMP4* (rs17563), *TGFA* (rs11466297), and *IRF6* (rs2235371) polymorphisms on the occurrence of NSCL/P in Indian population. The results showed that the *MTHFR* (1801133), *BMP4* (rs17563), and *TGFA* (rs11466297) polymorphisms have a significant effect on the occurrence of NSCL/P.

## Acknowledgement

The author would like to thank DST-INSPIRE, Ministry of Science and Technology, India Sanjay Gandhi Post Graduate Institute of Medical Sciences SGP GIMS, Lucknow, Uttar Pradesh and the Smile Train Foundation.

## References

- Balaji SM. Burden of orofacial clefting in India, 2016: A global burden of disease approach. *Ann Maxillofac Surg* 2018;8(1):91-100.
- Dixon MJ, Marazita ML, Beaty TH, Murray JC. Cleft lip and palate: understanding genetic and environmental influences. *Nat Rev Genet* 2011;12(3):167-78.
- Mossey PA, Little J, Munger RG, Dixon MJ, Shaw WC. 2009 Cleft lip and palate. *Lancet* 2009;374(9703):1773-85.
- Butali A, Mossey PA, Adeyemo WL, Jezewski PA, Onwuamah CK, Ogunlewe MO, et al. Genetic studies in the Nigerian population implicate an MSX1 mutation in complex oral facial clefting disorders. *Cleft Palate Craniofac J* 2011;48(6):646-53.
- Shi M, Christensen K, Weinberg CR, Romitti P, Bathum L, Lozada A. et al. Orofacial cleft risk is increased with maternal smoking and specific detoxification-gene variants. *Am J Hum Genet* 2007;80(1):76-90.
- Dada LA, Paz C, Mele P, Solano AR, Cornejo Maciel F, Podesta EJ. The cytosol as site of phosphorylation of the cyclic AMP-dependent protein kinase in adrenal steroidogenesis. *J Steroid Biochem Mol Biol* 1991;39(6):889-96.
- Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. *Nat Genet* 1994;7(2):195-200.
- Nie X, Luukko K, Kettunen P. BMP signalling in craniofacial development. *Int J Dev Biol* 2006;50(6):511-21.
- Kempa I, Ambrozaitytė L, Stavusis J, Akota I, Barkane B, Krumina A. et al. Association of *BMP4* polymorphisms with non-syndromic cleft lip with or without cleft palate and isolated cleft palate in Latvian and Lithuanian populations. *Stomatologija* 2014;16(3):94-101.
- Araújo T. K. Simioni M. Félix T. M. de Souza L. T. Fontes M. Í. Monlleó, I. L. Souza, J. Fett-Conte AC, Secolin R, Lopes-Cendes I, Maurer-Morelli CV, Gil-da-Silva-Lopes VL. Preliminary analysis of the nonsynonymous polymorphism rs17563 in *BMP4* gene in Brazilian popu-

- lation Suggests protection for nonsyndromic cleft lip and palate. *Plast Surg Int* 2012;2012:247104.
11. Saket M, Saliminejad K, Kamali K, Moghadam FA, Anvar NE, Khorram Khorshid H. R. 2016. BMP2 and BMP4 variations and risk of non-syndromic cleft lip and palate. *Arch Oral Biol* 2016;72:134-7.
  12. Vieira AR. Association between the transforming growth factor alpha gene and nonsyndromic oral clefts: a HuGE review. *Am J Epidemiol* 2006;163(9):790-810.
  13. Lu XC, Yu W, Tao Y, Zhao PL, Li K, Tang LJ, et al. Contribution of transforming growth factor  $\alpha$  polymorphisms to nonsyndromic orofacial clefts: a HuGE review and meta-analysis. *Am J Epidemiol* 2014;179(3):267-81.
  14. Ardinger HH, Buetow KH, Bell GI, Bardach J, VanDenmark DR, Murray JC. Association of genetic variation of the transforming growth factor-alpha gene with cleft lip and palate. *Am J Hum Genet* 1989;45(3):348-53.
  15. Ebadifar A, Khorram Khorshid HR, Saliminejad K, Kamali K, Aghakhani Moghadam F, Esmaili Anvar N, et al. Association of transforming growth factor alpha polymorphisms with nonsyndromic cleft lip and palate in Iranian population. *Avicenna J Med Biotechnol* 2015;7(4):168-72.
  16. Zuccherro TM, Cooper ME, Maher BS, Daack-Hirsch S, Nepomuceno B, Ribeiro L, et al. Interferon regulatory factor 6 (IRF6) gene variants and the risk of isolated cleft lip or palate. *N Engl J Med* 2004;351(8):769-80.
  17. Kondo S, Schutte BC, Richardson RJ, Bjork BC, Knight AS, Watanabe Y, et al. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. *Nat Genet* 2002;32(2):285-9.
  18. Rahimov F, Marazita ML, Visel A, Cooper ME, Hitchler MJ, Rubini M, et al. Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip. *Nat Genet* 2008;40(11):1341-7.
  19. Nan X, Liu M, Yuan G. [Zhonghua zheng xing wai ke za zhi Zhonghua zhengxing waikexue zazhi]. *Zhonghua Zheng Xing Wai Ke Za Zhi* 2014;30(4):265-9. Chinese.
  20. Zhao M, Ren Y, Shen L, Zhang Y, Zhou B. Association between MTHFR C677T and A1298C polymorphisms and NSCL/P risk in Asians: a meta-analysis. *PloS One* 2014;9(3):e88242.
  21. Mills JL, Kirke PN, Molloy AM, Burke H, Conley MR, Lee YJ, et al. Methylenetetrahydrofolate reductase thermolabile variant and oral clefts. *Am J Med Genet* 1999;86(1):71-4.
  22. Murthy J, Gurramkonda VB, Karthik N, Lakkakula BV. MTHFR C677T and A1298C polymorphisms and risk of nonsyndromic orofacial clefts in a south Indian population. *Int J Pediatr Otorhinolaryngol* 2014;78(2):339-42.
  23. Ali A, Singh KS, Raman R. MTHFR 677TT alone and IRF6 820GG together with MTHFR 677CT, but not MTHFR A1298C, are risks for nonsyndromic cleft lip with or without cleft palate in an Indian population. *Genet Test Mol Biomarkers* 2009;13(3):355-60.
  24. Wang W, Jiao XH, Wang XP, Sun XY, Dong C. MTR, MTRR, and MTHFR gene polymorphisms and susceptibility to nonsyndromic cleft lip with or without cleft palate. *Genet Test Mol Biomarkers* 2016;20(6):297-303.
  25. Sözen MA, Tolarova MM, Spritz RA. The common MTHFR C677T and A1298C variants are not associated with the risk of non-syndromic cleft lip/palate in northern Venezuela. *Journal of genetics and genomics. J Genet Genomics* 2009 May;36(5):283-8.
  26. Shotelersuk V, Ittiwut C, Siriwan P, Angspatt A. Maternal 677CT/1298AC genotype of the MTHFR gene as a risk factor for cleft lip. *J Med Genet* 2003;40(5):e64.
  27. Pezzetti F, Martinelli M, Scapoli L, Carinci F, Palmieri A, Marchesini J, et al. Maternal MTHFR variant forms increase the risk in offspring of isolated nonsyndromic cleft lip with or without cleft palate. *Hum Mutat* 2004;24(1):104-5.
  28. de Araujo TK, Secolin R, Félix TM, de Souza LT, Fontes MÍ, Monlleó IL, et al. A multicentric association study between 39 genes and nonsyndromic cleft lip and palate in a Brazilian population. *J Craniomaxillofac Surg* 2016;44(1):16-20.
  29. Hu YY, Qin CQ, Deng MH, Niu YM, Long X. Association between BMP4 rs17563 polymorphism and NSCL/P risk: a meta-analysis. *Dis Markers* 2015;2015:763090.
  30. Chen Q, Wang H, Hetmanski JB, Zhang T, Ruczinski I, Schwender H, et al. BMP4 was associated with NSCL/P in an Asian population. *PLoS One* 2012;7(4):e35347.
  31. Holder SE, Vintiner GM, Farren B, Malcolm S, Winter RM. Confirmation of an association between RFLPs at the transforming growth factor-alpha locus and nonsyndromic cleft lip and palate. *J Med Genet* 1992;29(6):390-2.
  32. Tanabe A, Taketani S, Endo-Ichikawa Y, Tokunaga R, Ogawa Y, Hiramoto M. Analysis of the candidate genes responsible for non-syndromic cleft lip and palate in Japanese people. *Clin Sci (Lond)* 2000;99(2):105-11.
  33. Stoll C, Qian JF, Feingold J, Sauvage P, May E. Genetic variation in transforming growth factor alpha: possible association of BamHI polymorphism with bilateral sporadic cleft lip and palate. *Human Genet* 1993;92(1):81-2.
  34. Lidral AC, Murray JC, Buetow KH, Basart AM, Schearer H, Shiang R, et al. Studies of the candidate genes TGFB2, MSX1, TGFA, and TGFB3 in the etiology of cleft lip and palate in the Philippines. *Cleft Palate Craniofac J* 1997;34(1):1-6.
  35. Jugessur A, Rahimov F, Lie RT, Wilcox AJ, Gjessing HK, Nilsen RM, et al. Genetic variants in IRF6 and the risk of facial clefts: single-marker and haplotype-based analyses in a population-based case-control study of facial clefts in Norway. *Genet Epidemiol* 2008;32(5):413-24.
  36. Huang Y, Wu J, Ma J, Beaty TH, Sull JW, Zhu L, et al. Association between IRF6 SNPs and oral clefts in West China. *J Dent Res* 2009;88(8):715-8.
  37. Gurramkonda VB, Syed AH, Murthy J, Lakkakula B. IRF6 rs2235375 single nucleotide polymorphism is associated with isolated non-syndromic cleft palate but not with cleft lip with or without palate in South Indian population. *Braz J Otorhinolaryngol* 2018;84(4):473-477.